Lv2
176 积分 2022-11-20 加入
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2个月前
已完结
RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs
3个月前
已完结
Non-small-cell lung cancer
3个月前
已完结
Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer
11个月前
已完结
High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response
11个月前
已完结
MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer
1年前
已完结
Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
1年前
已完结
Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer
1年前
已完结
Acquired resistance in cancer: towards targeted therapeutic strategies
1年前
已完结
皖公网安备34019202002308
